NCT06563596 - Epco, Zanu, Ritux for R/R FL or MZL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 21, 2025

Primary Completion Date

March 1, 2028

Study Completion Date

March 1, 2030

Conditions

Follicular LymphomaLymphomaNon-Hodgkin LymphomaRelapsed LymphomaRefractory LymphomaMarginal Zone Lymphoma

Interventions

DRUG

Zanubrutinib

Bruton tyrosine kinase inhibitor, 80 mg immediate-release capsule, taken orally per protocol.

DRUG

Rituximab

Chimeric anti-CD20 monoclonal antibody, 10 or 50 mL single-use vials, via intravenous infusion per institutional standard.

DRUG

Epcoritamab

Bispecific antibody, 5 or 60 mg/mL vials, via subcutaneous (under the skin) injection per protocol.

Trial Locations (2)

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

RECRUITING

Dana-Farber Cancer Institute, Boston